Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer. 2. Oktober 2018 Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018. Oncol Res Treat 41 (suppl 4)(P916). Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry. Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018. Oncol Res Treat 41… Weiterlesen Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2. M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018. Oncol Res Treat 41 (suppl 4)(P610). Weiterlesen